Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study-Reference-Cited by-同舟云学术

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study

Published:2017-04-07 Issue:5 Volume:69 Page:1016-1027
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Stohl William¹,Schwarting Andreas²,Okada Masato³,Scheinberg Morton⁴,Doria Andrea⁵,Hammer Anne E.⁶,Kleoudis Christi⁷,Groark James⁸,Bass Damon⁸,Fox Norma Lynn⁹,Roth David⁸,Gordon David⁸

Affiliation:

1. University of Southern CaliforniaLos Angeles

2. Acura Kliniken Rheinland‐Pfalz AGBad Kreuznach Germany

3. St. Luke's International HospitalTokyo Japan

4. Rheumatology Hospital Abreu SodreSão Paulo Brazil

5. University of PaduaPadua Italy

6. GlaxoSmithKline, Research Triangle Park North Carolina

7. ParexelRaleigh‐Durham North Carolina

8. GlaxoSmithKlinePhiladelphia Pennsylvania

9. GlaxoSmithKlineRockville Maryland

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.40049

Reference46 articles.

1. BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth

2. BLyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator

3. Baff Binds to the Tumor Necrosis Factor Receptor–Like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population

4. Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response

5. Baff Mediates Survival of Peripheral Immature B Lymphocytes

Cited by 271 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients’ Preferences for Systemic Lupus Erythematosus Treatments—A Discrete Choice Experiment;The Patient - Patient-Centered Outcomes Research;2024-01-25

2. Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins;Clinical Pharmacology & Therapeutics;2024-01-18

3. Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab;Rheumatology;2024-01-12

4. Fragility of randomised controlled trials for systemic lupus erythematosus and lupus nephritis therapies;Lupus Science & Medicine;2024-01

5. Homoeostatic Versus Pathogenic Autoantibodies: Origin, Structure and Effector Functions;Molecular Biology of B Cells;2024